MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - THEWEST.COM.AU - Business - 10/Jul 07:01
Radiopharm unveils landmark human lung cancer trial
Radiopharm Theranostics has kicked off the first phase of clinical trials testing its “RAD 204” treatment aimed at beating the most common type of lung cancer after dosing its first patient in New South Wales.
Articles similaires
Cleo Commences U.S. Clinical Trials
entrepreneur.ca - 06/Sep 00:02
Cleo Commences U.S. Clinical Trials Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to...
AI Transforms Gene Mutations Prediction in Lung Cancer
medindia.net - 09/Sep 03:52
Artificial intelligence revolutionizes gene mutation prediction in lung cancer, offering more accurate, faster insights for personalized treatment...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
drugs.com - 05/Sep 04:09
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
drugs.com - 06/Sep 07:09
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
haei.org - 06/Sep 18:54
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
Les derniers communiqués
-
Aucun élément